Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Xtant Medical Holdings, Inc.XTNT · Entity 7196 | Director · Interim CEO | October 15, 2018 | October 15, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Xtant Medical Holdings, Inc.
Report date October 15, 2018 · Filed October 15, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.22 · Expires 2028-10-15 | Direct | 240,000 |
Reported balance
After 2018-10-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-10-15 · Grant · Acquired 240,000 · Balance 240,000 F2: This option vests with respect to 10,000 of the shares subject to the option on the 15th day of each of the twenty-four (24) months commencing on November 15, 2018, subject to such Reporting Person's continued employment as Chief Executive Officer of Xtant Medical Holdings, Inc. |
| Common Stock, $0.000001 par valueSEC Table I · non-derivative | Direct | 20,833 |
Reported balance
Holding disclosure · report date 2018-10-15 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 20,833 F1: These shares are subject to vesting pursuant to a restricted stock award granted under the Amended and Restated Xtant Medical Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are subject to vesting pursuant to a restricted stock award granted under the Amended and Restated Xtant Medical Equity Incentive Plan.
F2: This option vests with respect to 10,000 of the shares subject to the option on the 15th day of each of the twenty-four (24) months commencing on November 15, 2018, subject to such Reporting Person's continued employment as Chief Executive Officer of Xtant Medical Holdings, Inc.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 15, 2018 Filed Oct 15, 2018 20:08 UTC | Xtant Medical Holdings, Inc. XTNT · Entity 7196 | GrantStock Option (right to buy) · Derivative | 240,000 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001235802-18-000155 · primary_doc.xml · derivative · entry 2 Mainelli Michael · CIK 0001315983 · Director · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,000 Underlying: Common Stock · 240,000 shares Expires 2028-10-15 F2 · derivative.exercise_date: This option vests with respect to 10,000 of the shares subject to the option on the 15th day of each of the twenty-four (24) months commencing on November 15, 2018, subject to such Reporting Person's continued employment as Chief Executive Officer of Xtant Medical Holdings, Inc. Read SEC document |
| April 08, 2018 Filed Apr 10, 2018 23:00 UTC | Xtant Medical Holdings, Inc. XTNT · Entity 7196 | GrantCommon Stock | 20,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-020003 · tv490828_4.xml · nonDerivative · entry 1 Mainelli Michael · CIK 0001315983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,833 F1 · shares: The common stock vests as follows: (i) 10,416 shares of common stock vests on February 15, 2019, and (ii) 10,417 shares of common stock vests of February 15, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.